Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Enterprise Value: 2020-2025

Historic Enterprise Value for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $2.4 billion.

  • Apellis Pharmaceuticals' Enterprise Value fell 23.65% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 40.49%. This contributed to the annual value of $3.6 billion for FY2024, which is 47.24% down from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Enterprise Value is $2.4 billion, which was up 31.77% from $1.8 billion recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Enterprise Value peaked at $10.0 billion during Q2 2023, and registered a low of $1.8 billion during Q2 2025.
  • For the 3-year period, Apellis Pharmaceuticals' Enterprise Value averaged around $4.7 billion, with its median value being $4.0 billion (2023).
  • Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 178.80% in 2022, then tumbled by 64.72% in 2025.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Enterprise Value stood at $3.4 billion in 2021, then spiked by 50.72% to $5.2 billion in 2022, then spiked by 30.52% to $6.7 billion in 2023, then slumped by 47.24% to $3.6 billion in 2024, then dropped by 23.65% to $2.4 billion in 2025.
  • Its last three reported values are $2.4 billion in Q3 2025, $1.8 billion for Q2 2025, and $2.4 billion during Q1 2025.